Bicara Therapeutics Inc. (BCAX)
Who owns Bicara Therapeutics Inc. (BCAX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 55.8% of the shares are freely tradable; institutional investors hold 104.3%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 11.04 | 7,255,993 | +4.3 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 10.05 | 6,605,780 | +94.2 | 03/31/2026 |
| Siren, L.L.C. | 8.83 | 5,802,970 | +11.2 | 03/31/2026 |
| Vestal Point Capital LP | 8.26 | 5,425,000 | +51.7 | 03/31/2026 |
| Deep Track Capital, LP | 6.18 | 4,062,500 | +55.4 | 03/31/2026 |
| HHG PLC | 5.08 | 3,339,218 | +26.2 | 03/31/2026 |
| Red Tree Management, LLC | 4.83 | 3,170,509 | +0.0 | 03/31/2026 |
| TPG GP A, LLC | 4.58 | 3,010,425 | +0.0 | 03/31/2026 |
| BlackRock Inc | 4.33 | 2,843,707 | +12.5 | 03/31/2026 |
| Omega Fund Management LLC | 3.64 | 2,392,150 | +8.5 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 28 | 29.68 | 831 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 9,972 | 28.42 | 283,367 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Other | 10,000 | 3.79 | 37,898 |
| 21. Apr 2026 | Ivan Hyep | CFO | Sell | 9,200 | 23.00 | 211,600 |
| 20. Apr 2026 | Claire Mazumdar | CEO | Sell | 15,000 | 23.61 | 354,150 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.